Home
→
Recerca: articles, congressos, llibres
→
Departament de Medicina i Ciències de la Vida
→
Articles (Departament de Medicina i Ciències de la Vida)
→
Browsing Articles (Departament de Medicina i Ciències de la Vida) by Author

Browsing Articles (Departament de Medicina i Ciències de la Vida) by Author "Haba Rodríguez, Juan de la"

Now showing items 1-3 of 3

In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

Artigas, Laura; Coma Camprodón, Mireia; Matos Filipe, Pedro; Aguirre Plans, Joaquim, 1993-; Farrés, Judith; Valls, Raquel; Fernández Fuentes, Narcís; Haba Rodríguez, Juan de la; Olvera, Alex; Barbera, Jose; Morales, Rafael; Oliva Miguel, Baldomero; Mas, José Manuel (Public Library of Science (PLoS), 2020)

From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, ...
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Tibau, Ariadna; Martínez, María Teresa; Ramos, Manuel; Cruz-Merino, Luis; Santaballa, Ana; O'Connor, Miriam; Martínez-Jáñez, Noelia; Moreno, Fernando; Fernández, Isaura; Virizuela, Juan Antonio; Alarcón, Jesús; Haba Rodríguez, Juan de la; Sánchez-Rovira, Pedro; Albacar, Cinta Rosa; Bueno Muiño, Carolia; Kelly, Catherine; Casas Sanahuja, Maribel; Bezares, Susana; Rosell, Libertad; Albanell Mestres, Joan (SAGE Publications, 2023)

Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC). ...
Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Alba, Emilio; Albanell Mestres, Joan; Haba Rodríguez, Juan de la; Barnadas, Agustí; Calvo, Lourdes; Sánchez-Rovira, Pedro; Ramos, Manuel; Rojo, Federico; Burgués, Octavio; Carrasco, Eva María; Caballero, Rosalía; Porras, Ignacio; Tibau, Ariadna; Cámara, Maria del Carmen; Lluch, Ana (Nature Research, 2014)

Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive ...

Now showing items 1-3 of 3

Search DSpace

Advanced Search

Browse

All of DSpace
This Collection

My Account

Compliant to Partaking

Browsing Articles (Departament de Medicina i Ciències de la Vida) by Author "Haba Rodríguez, Juan de la"

Browsing Articles (Departament de Medicina i Ciències de la Vida) by Author "Haba Rodríguez, Juan de la"

Search DSpace

Browse

All of DSpace

This Collection

My Account